<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="452">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04362943</url>
  </required_header>
  <id_info>
    <org_study_id>PAS-BAR-2020-04</org_study_id>
    <nct_id>NCT04362943</nct_id>
  </id_info>
  <brief_title>Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults</brief_title>
  <acronym>COVID-AGE</acronym>
  <official_title>Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Complejo Hospitalario Universitario de Albacete</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Complejo Hospitalario Universitario de Albacete</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective clinical-epidemiological study aimed at characterizing COVID-19 disease in
      adults older than 70 years, hospitalized in the &quot;Perpetuo Socorro&quot; Hospital of Albacete
      (Spain) from 09/03/2020 until 20/04/2020. Secondary objectives will be to analyze
      clinical-epidemiological characteristics of COVID-19 patients treated with Baricitinib or
      Anakinra, and to describe the efficacy and secondary effects of those drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: Retrospective postauthorization study. Registry study. Setting: COVID Unit, &quot;Perpetuo
      Socorro&quot; Hospital of Albacete (Spain). Participants: Adults older than 70 years hospitalized
      for COVID-19 disease between 09/03/2020 and 20/04/2020. All patients will be included without
      exclussion criteria.

      Measurements:

        -  Age, sex, residency.

        -  Functional assessment: Barthel index, Katz index, Functional Ambulation Classification.

        -  Cognitive assessment: Reisberg´s Global Deteriorating Scale.

        -  Comorbidity: Charlson index, disease count.

        -  Chronic medicines consumed.

        -  Disease related symptoms.

        -  Lab determinations: White cells, neutrophyl count, lymphocyte count, platelets,
           haemoglobin, INR, fibrinogen, D-Dimer, Ferritin, CRP, IL-6, urea, creatinin, AST, ALT,
           CK.

        -  Thorax X-ray findings: COVID affectation, severity, pleural effusion, heart failure
           signs, pneumothorax.

        -  Drugs used during hospitalization, number of days of treatment and total doses:
           Anakinra, Baricitinib, Glucocorticoids, Antivirals (Lopinavir/Ritonavir,
           Emtricitabina/Tenofovir), Azitromycin, Ceftriaxone, Hidroxychloroquin.

        -  Geriatric syndroms: Delirium, immobility, dysphagia, pressure ulcers.

        -  Outcomes: Mortality at discharge, institucionalización at discharge, length of stay,
           change in lab results, change in X-ray results, change in function at discharge.

      Registry procedures: Medical chart review by trained Geriatricians, pharmachological chart
      review by expert Pharmacists, X-ray review by trained radiologists. All data will be included
      in an anonimyzed database for further analysis by investigators, and supervised by Principal
      Investigator.

      Regulatory status: The protocol was approved by the Ethics review committee of Albacete
      (number 2020-21 from 20/04/2020) and by the Spanish Medicines Agency (AEMPS) who gave a
      &quot;Postauthorization Study&quot; classification (number PAS-BAR-2020-04. 20/04/2020).

      Analysis: Two stage analysis will be conducted. In first one, efficacy and security analysis
      of the 99 patients that have received either Baricitinib or Anakinra will be conducted, and
      in the second one, clinical-epidemiological analysis of the complete sample, n=576, will be
      realized.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 month</time_frame>
    <description>Mortality for all causes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>X-ray changes</measure>
    <time_frame>1 month</time_frame>
    <description>Changes from admission to discharge thorax X-rays assessed by blinded radiologists</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability changes</measure>
    <time_frame>1 month</time_frame>
    <description>Changes from admission to discharge in Barthel index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulation changes</measure>
    <time_frame>1 month</time_frame>
    <description>Changes from admission to discharge in Functional Ambulation Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphocyte count changes</measure>
    <time_frame>1 month</time_frame>
    <description>Changes from admission to discharge in lymphocyte count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein changes</measure>
    <time_frame>1 month</time_frame>
    <description>Changes from admission to discharge in C-Reactive Protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin changes</measure>
    <time_frame>1 month</time_frame>
    <description>Changes from admission to discharge in Ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-Dimer changes</measure>
    <time_frame>1 month</time_frame>
    <description>Changes from admission to discharge in D-Dimer</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">576</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Complete sample</arm_group_label>
    <description>Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 in the &quot;Perpetuo Socorro&quot; Hospital of Albacete (Spain)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib</arm_group_label>
    <description>Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 and receiving Baricitinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anakinra</arm_group_label>
    <description>Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 and receiving Anakinra.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib or Anakinra</intervention_name>
    <description>Treatment with either Baricitinib or Anakinra during hospitalization, in real world, and under usual clinical care.</description>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_label>Baricitinib</arm_group_label>
    <arm_group_label>Complete sample</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and
        20/04/2020, in the &quot;Perpetuo Socorro&quot; Hospital of Albacete (Spain).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and
             20/04/2020, in the &quot;Perpetuo Socorro&quot; Hospital of Albacete (Spain).

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Abizanda Soler, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head Geriatrics Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro Abizanda Soler, MD,PhD</last_name>
    <phone>+34636557437</phone>
    <email>pabizanda@sescam.jccm.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Almudena Avendaño Céspedes, RN, PhD</last_name>
    <phone>+34967597684</phone>
    <email>aavendanoc@sescam.jccm.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Abizanda Soler, MD,PhD</last_name>
      <phone>+34967597684</phone>
      <email>pabizanda@sescam.jccm.es</email>
    </contact>
    <contact_backup>
      <last_name>Almudena Avendaño Céspedes, RN, PhD</last_name>
      <phone>+34967597684</phone>
      <email>aavendanoc@sescam.jccm.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Complejo Hospitalario Universitario de Albacete</investigator_affiliation>
    <investigator_full_name>Pedro Abizanda</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Older adults</keyword>
  <keyword>Hospitalization</keyword>
  <keyword>Baricitinib</keyword>
  <keyword>Anakinra</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Security</keyword>
  <keyword>Mortality</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared on request. Study protocol, statistical analysis and clinical study report will be shared when data will be published in a Journal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>At data Journal publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

